• Return to Headlines

Tg Therapeutics Down 45.4% Since SmarTrend Downtrend Call (TGTX)

By Amy Schwartz

SmarTrend identified a Downtrend for Tg Therapeutics (NASDAQ:TGTX) on September 17th, 2018 at $10.15. In approximately 2 months, Tg Therapeutics has returned 45.42% as of today's recent price of $5.54.

Over the past year, Tg Therapeutics has traded in a range of $4.20 to $17.35 and is now at $5.54, 32% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 9.4% while the 200-day MA has slid 1%.

TG Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of innovative pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is developing two therapies targeting hematological malignancies, specifically, relapsed, and refractory non-Hodgkins lymphoma.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Tg Therapeutics.

Log in and add Tg Therapeutics (TGTX) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights tg therapeutics

Ticker(s): TGTX